- Home
- ADVM
as 05-30-2025 3:30pm EST
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 59.5M | IPO Year: | 2014 |
| Target Price: | $26.40 | AVG Volume (30 days): | 430.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.78 - $10.14 | Next Earning Date: | 05-14-2025 |
| Revenue: | $1,000,000 | Revenue Growth: | -72.22% |
| Revenue Growth (this year): | -83.85% | Revenue Growth (next year): | 42.58% |
Stock Insider Trading Activity of Adverum Biotechnologies Inc. (ADVM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fischer Laurent | ADVM | CEO, PRESIDENT AND DIRECTOR | May 15 '25 | Sell | $2.00 | 9,126 | $18,252.00 | 87,488 | |
| Soparkar Peter | ADVM | CHIEF OPERATING OFFICER | May 15 '25 | Sell | $2.00 | 2,960 | $5,920.00 | 39,154 | |
| Leonard Braden Michael | ADVM | 10% Owner | Apr 22 '25 | Buy | $2.99 | 350,000 | $1,048,950.00 | 191,800 | |
| Leonard Braden Michael | ADVM | 10% Owner | Mar 31 '25 | Buy | $4.21 | 34,775 | $147,075.63 | 191,800 | |
| Leonard Braden Michael | ADVM | 10% Owner | Mar 26 '25 | Buy | $5.11 | 111,000 | $566,791.62 | 191,800 | |
| Leonard Braden Michael | ADVM | 10% Owner | Mar 18 '25 | Buy | $4.97 | 117,941 | $587,574.62 | 191,800 |
Latest Adverum Biotechnologies Inc. News
ADVM Breaking Stock News: Dive into ADVM Ticker-Specific Updates for Smart Investing
MT Newswires
17 days ago
RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk
Associated Press Finance
17 days ago
Adverum Biotechnologies: Q1 Earnings Snapshot
GlobeNewswire
17 days ago
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
Simply Wall St.
a month ago
3 Penny Stocks Under $300M Market Cap To Consider
GlobeNewswire
a month ago
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 04/29/2025
MT Newswires
a month ago
Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing
MT Newswires
a month ago
Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating
Compare ADVM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADVM Adverum Biotechnologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.